A stem cell–based platform for the discovery and development of antitumor therapeutic antibodies to novel targets

Recombinant Antibodies for Immunotherapy

Volumn , Issue , 2009, Pages 313-335

  Mather, Jennie P ^a   Fieger, Claudia ^a   Liang, Tony W ^a   King, Kathleen L ^a   Li, Jonathan ^a   Young, Peter ^a   Beltejar, Claude ^a   Potts, Beverly ^a   Licea, Monica ^a   Loo, Deryk ^a  

^a Raven Biotechnologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84856113427     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511596773.024     Document Type: Chapter

References (23)

1. Adams, G.P. and L.M. Weiner (2005). "Monoclonal antibody therapy of cancer." Nat Biotechnol 23(9): 1147-57.
2. Barros, L.F., T. Hermosilla, et al. (2001). "Necrotic volume increase and the early physiology of necrosis." Comp Biochem Physiol A Mol Integr Physiol 130(3): 401-9.
3. Carles-Kinch, K., K.E. Kilpatrick, et al. (2002). "Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior." Cancer Res 62(10): 2840-7.
4. Dinh, P., E. de Azambuja, et al. (2007). "Trastuzumab for early breast cancer: current status and future directions." Clin Adv Hematol Oncol 5(9): 707-17.
5. Ewer, M.S. and J.A. O'Shaughnessy (2007). "Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer." Clin Breast Cancer 7(8): 600-7.
6. Harlow, E. and D. Lane (1988). Antibodies: a laboratory manual, Cold Spring Harbor Laboratory Press.
7. Johnson, J.I., S. Decker, et al. (2001). "Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials." Br J Cancer 84(10): 1424-31.
8. Johnson, P. and M. Glennie (2003). "The mechanisms of action of rituximab in the elimination of tumor cells."Semin Oncol 30(1 Suppl. 2): 3-8.
9. Klinger, M., H. Farhan, et al. (2004). "Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors." Cancer Res 64(3): 1087-93.
10. Li, J.C. and R. Li (2007). "RAV12 accelerates the desensitization of Akt/PKB pathway of insulin-like growth factor I receptor signaling in COLO205." Cancer Res 67(18): 8856-64.
11. Liu, X., T. Van Vleet, et al. (2004). "The role of calpain in oncotic cell death." Annu Rev Pharmacol Toxicol 44: 349-70.
12. Loo, D., M. Armanini, et al. (2008). "The RAV12monoclonal antibody recognizes theN-linked glycotope RAAG12; expression in human normal and tumor tissue." Arch Pathol and Lab Medicine. In press.
13. Loo, D., N. Pryer, et al. (2007). "The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo." Mol Cancer Ther 6(3): 856-65.
14. Loo, D.T., J.I. Fuquay, et al. (1987). "Extended culture of mouse embryo cells without senescence: inhibition by serum." Science 236(4798): 200-2.
15. Ma, F., C. Zhang, et al. (2001). "Molecular cloning of Porimin, a novel cell surface receptor mediating oncotic cell death." Proc Natl Acad Sci USA 98(17): 9778-83.
16. Majno, G. and I. Joris (1995). "Apoptosis, oncosis, and necrosis. An overview of cell death." Am J Pathol 146(1): 3-15.
17. Mather, J.P. and P.F. Young, inventors; Raven Biotechnologies, Inc., assignee. Animal model for toxicology and dose prediction. United States patent US 20, 040, 045, 045. 2004 March 4.
18. Matsuoka, S., Y. Asano, et al. (1995). "A novel type of cell death of lymphocytes induced by a monoclonal antibody without participation of complement." J Exp Med 181(6): 2007-15.
19. Parmar, H., P. Young, et al. (2002). "A novel method for growing human breast epithelium in vivo using mouse and human mammary fibroblasts." Endocrinology 143(12): 4886-96.
20. Smith, M.R. (2003). "Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance." Oncogene 22(47): 7359-68.
21. Suarez, Y., L. Gonzalez, et al. (2003). "Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells." Mol Cancer Ther 2(9): 863-72.
22. Trump, B.F., I.K. Berezesky, et al. (1997). "The pathways of cell death: oncosis, apoptosis, and necrosis." Toxicol Pathol 25(1): 82-8.
23. Zhang, Y., L. Xiang, et al. (2007). "Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors." Proc Natl Acad Sci USA 104(43): 17099-104.